

Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: facing the perfect storm

Raúl Recio , Jennifer Villa , Esther Viedma ,
María Ángeles Orellana , Jaime Lora-Tamayo , Fernando Chaves

PII: S0924-8579(18)30095-5
DOI: 10.1016/j.ijantimicag.2018.03.018
Reference: ANTAGE 5409

To appear in: *International Journal of Antimicrobial Agents*

Received date: 14 January 2018
Revised date: 16 March 2018
Accepted date: 27 March 2018

Please cite this article as: Raúl Recio , Jennifer Villa , Esther Viedma , María Ángeles Orellana , Jaime Lora-Tamayo , Fernando Chaves , Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: facing the perfect storm, *International Journal of Antimicrobial Agents* (2018), doi: 10.1016/j.ijantimicag.2018.03.018

Highlights

- We present a well characterized cohort of 64 patients with bacteraemia caused by *Pseudomonas aeruginosa*, with a 42% crude 30-day mortality.
- Severe clinical presentation and respiratory source of bacteraemia were independent risk factors for 30-day crude mortality.
- ST235 clone, associated to GES-5-carbapenemase production and *exo*U-positive genotype, showed a severe clinical behaviour as compared to other extensively drug-resistant (XDR) strains.
- Ceftazidime-avibactam was active in 100% of XDR isolates belonging to the GES-5-carbapenemase producing ST235 clone, but ineffective against VIM-2-carbapenemase producing ST175 clone.